News

Genentech, a member of the Roche Group announced that the U.S. Food & Drug Administration (FDA) has approved a randomized, double-blind, placebo-controlled Phase III clinical trial…
Read More...

Soligenix, Inc. (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet…
Read More...

As part of the U.S. Food and Drug Administration's ongoing efforts to address the coronavirus pandemic (COVID-19), the agency issued a new guidance to sponsors and healthcare providers…
Read More...

Tarveda Therapeutics, Inc. and SciClone Pharmaceuticals International Ltd. announced that they have entered into a licensing agreement for PEN-866, the initial clinical program from…
Read More...

Junshi Biosciences announced that it has recently signed a collaboration agreement with the Institute of Microbiology of the Chinese Academy of Sciences (IMCAS) to jointly develop…
Read More...

Ridgeback Biotherapeutics LP, a closely held biotechnology company, and Drug Innovations at Emory (DRIVE), LLC, a not-for-profit biotechnology company wholly owned by Emory University,…
Read More...

Dragonfly Therapeutics, Inc. announced an expansion of its strategic collaboration with Merck, known as MSD outside the United States and Canada to discover, develop and commercialize a…
Read More...

Novartis Pharma K.K. announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) approved Zolgensma (onasemnogene abeparvovec) for the treatment of spinal muscular atrophy…
Read More...

Emergent BioSolutions Inc. announced that it has entered into an agreement with Vaxart, Inc. a clinical-stage biotechnology company, whereby Emergent has agreed to utilize its…
Read More...

Roche announced we are working with the Food & Drug Administration (FDA) to initiate a randomised, double-blind, placebo-controlled Phase III clinical trial in collaboration with…
Read More...

IMV Inc. announced that it is advancing the clinical development of a DPX-based vaccine candidate against COVID-19. Vaccines against infectious disease have been a core part of IMV’s…
Read More...

Asklepios BioPharmaceutical, Inc. (AskBio) announced that it has entered into a research collaboration and licensing agreement with the University of North Carolina at Chapel Hill (UNC)…
Read More...

Moderna, Inc. a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients,…
Read More...

Pfizer Inc. and BioNTech SE announced that the companies have agreed to a letter of intent regarding the co-development and distribution (excluding China) of a potential mRNA-based…
Read More...

Merck, known as MSD outside the United States and Canada, announced top-line efficacy results from two ongoing pivotal Phase 3 trials (COUGH-1 and COUGH-2) evaluating the efficacy and…
Read More...

High-level results from the final analysis of the Phase III CASPIAN trial showed AstraZeneca’s Imfinzi (durvalumab) in combination with a choice of standard-of-care (SoC) chemotherapies…
Read More...

RoosterBio Inc. announces a clinical supply and manufacturing collaboration agreement with pioneering gene circuit company Senti Biosciences, Inc. (Senti) to accelerate the clinical…
Read More...

OSE Immunotherapeutics SA and Servier announced the execution of an amendment to the two-step global licensing option agreement for exclusive global rights to interleukin-7 receptor…
Read More...

Regeneron Pharmaceuticals, Inc. announced the latest progress in its efforts to discover and develop a novel multi-antibody cocktail that can be administered as prophylaxis before…
Read More...

Celltex Therapeutics Corporation, a Houston, Texas-based biotechnology company founded in 2011 and focused on spearheading breakthroughs in regenerative medicine using adult, autologous…
Read More...